izpis_h1_title_alt

Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes
ID Pajk, Stane (Author), ID Knez, Damijan (Author), ID Košak, Urban (Author), ID Zorović, Maja (Author), ID Brazzolotto, Xavier (Author), ID Coquelle, Nicolas (Author), ID Nachon, Florian (Author), ID Colletier, Jacques-Philippe (Author), ID Živin, Marko (Author), ID Stojan, Jure (Author), ID Gobec, Stanislav (Author)

.pdfPDF - Presentation file, Download (1,60 MB)
MD5: 409B34DEEF5881A8DE2B34B90529B0E9
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/14756366.2019.1710502 This link opens in a new window

Abstract
Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer's disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, reversible, and selective BChE inhibitors, we have developed the fluorescent probes that are selective towards human BChE. The most promising probes also maintain their inhibition of BChE in the low nanomolar range with high selectivity over acetylcholinesterase. Kinetic studies of probes reveal a reversible mixed inhibition mechanism, with binding of these fluorescent probes to both the free and acylated enzyme. Probes show environment-sensitive emission, and additionally, one of them also shows significant enhancement of fluorescence intensity upon binding to the active site of BChE. Finally, the crystal structures of probes in complex with human BChE are reported, which offer an excellent base for further development of this library of compounds.

Language:English
Keywords:butyrylcholinesterase, inhibitor, probe, fluorescence
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:Str. 498-505
Numbering:Vol. 35, iss. 1
PID:20.500.12556/RUL-125368 This link opens in a new window
UDC:616.894+616.892.3:615.2
ISSN on article:1475-6366
DOI:10.1080/14756366.2019.1710502 This link opens in a new window
COBISS.SI-ID:4869233 This link opens in a new window
Publication date in RUL:12.03.2021
Views:1168
Downloads:244
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of enzyme inhibition and medicinal chemistry
Shortened title:J. enzyme inhib. med. chem.
Publisher:Taylor & Francis
ISSN:1475-6366
COBISS.SI-ID:512255001 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:12.03.2021

Secondary language

Language:Slovenian
Keywords:patogeneza Alzheimerjeve bolezni, butiriliholinesteraza, zaviralci

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:L1-8157
Name:Razvoj multifunkcionalnih učinkovin za zdravljenje Alzheimerjeve bolezni

Funder:ARRS - Slovenian Research Agency
Project number:NC-0009
Name:Razvoj novih karbamatnih sond za holinesteraze

Funder:Other - Other funder or multiple funders
Funding programme:French Ministry of Armed Forces

Funder:Other - Other funder or multiple funders
Funding programme:Agence Nationale de la Recherche
Project number:ANR-12-BS07-0008–01

Funder:Other - Other funder or multiple funders
Funding programme:France Alzheimer Foundation
Project number:FA-AAP-2013–65-101349

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back